Correction to: Oncogene https://doi.org/10.1038/s41388-024-02945-1, published online 19 January 2024
Upon recent review of figures in this paper, the authors identified an overlap in certain areas of Figure 2d pertaining to the migration assay of C4-2 cells in the transwell experiment for the shSMYD2#1 and shSMYD2#2 groups. Upon re-examining the original data, they found that an image from the shSMYD2#1 condition was inadvertently mislabeled as shSMYD2#2-1 during archiving. This occurred as a filing error when handling the multiple images captured for each sample group. Owing to the minor overlap, this mistake was unfortunately not caught during multiple rounds of proofreading. The authos apologize for this oversight. This was unintentional clerical error, and does not affect the scientific conclusions of the study.
The original article has been corrected.
Original Fig 2d:
Corrected Fig 2d:
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Li, J., Hong, Z., Zhang, J. et al. Correction: Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide. Oncogene 45, 805–807 (2026). https://doi.org/10.1038/s41388-026-03690-3
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41388-026-03690-3
